Atrogi’s oral candidate mimics exercise to preserve muscle, improve metabolism and counter GLP-1–linked muscle loss.
The question of how to intervene pharmacologically in age-related metabolic decline without damaging the very tissues that preserve vitality has become a key challenge for longevity science. GLP-1 receptor agonists may be enjoying their moment in the sun, with headlines touting their capacity to drive weight loss and improve glycemic control – but concerns about their tendency to reduce lean mass have been increasingly voiced, particularly by those interested in aging well rather than simply growing thinner.
Now, Swedish biotech Atrogi has published preclinical and early clinical data that could signal a new direction. The company’s investigational oral therapy, ATR-258, activates skeletal muscle metabolism in a novel way, with data indicating that it supports fat loss and glycemic control while preserving – indeed, enhancing – lean muscle [1]. The approach is based on a highly selective signaling bias that avoids the problematic cardiovascular effects long associated with β2-agonists.
Longevity.Technology: As the longevity field continues to embrace GLP-1s for their powerful weight-loss and metabolic benefits, a nagging concern persists: the loss of muscle mass. For those interested in extending not just lifespan but healthspan, the trade-off between fat loss and lean mass preservation is increasingly untenable. Atrogi’s candidate, ATR-258, could offer a solution – tapping into skeletal muscle’s untapped potential not just as a metabolic engine but as a frontline therapeutic target. It’s no small thing to claim exercise-like benefits from a pill, but the notion of pharmacologically preserving muscle while enhancing fat loss is precisely the kind of next-generation intervention this field needs. In an aging society, where sarcopenia silently undercuts independence and quality of life, a drug that builds muscle without requiring a treadmill could be transformative.
There’s a subtle but profound shift in strategy here: rather than tackling weight loss through appetite suppression alone, this approach targets the muscle itself – revving up metabolism, increasing glucose uptake, and crucially, avoiding the cardiovascular downsides of older drugs in this space. That’s not just safer pharmacology; it’s smarter longevity thinking. If GLP-1s were Act I, ATR-258 may be Act II – preserving muscle, preventing frailty and enabling a more robust, active later life. The real promise lies in synergy: combining therapies that don’t just shrink us, but strengthen us.
A different path through muscle
At the heart of the Atrogi platform is a class of molecules that selectively activate β2-adrenergic receptors in skeletal muscle via a G protein-coupled receptor kinase (GRK)-biased mechanism [1]. This technical nuance – though not one likely to make headlines – matters. It allows for beneficial signaling in muscle tissue without triggering the problematic elevations in cyclic AMP that have historically been responsible for β2-agonists’ undesirable cardiac effects.
Atrogi’s Founder and CSO, Professor Tore Bengtsson, who is also senior author of the study, told Longevity.Technology that ATR-258 is designed to “selectively activate skeletal muscle metabolism through a novel, GRK2-biased signaling pathway.” This, he added, “mimics key molecular effects of exercise, boosting glucose uptake, protein synthesis, and mitochondrial function,” without triggering cardiovascular side effects.
The candidate compound ATR-258 was shown in Cell to improve glucose uptake and reduce fat mass in preclinical models, while increasing lean mass and avoiding muscle atrophy – particularly relevant when combined with liraglutide, a GLP-1 analog known to affect muscle adversely [1]. According to the authors, the mechanism bypasses traditional insulin signaling pathways, instead working through GRK2 activation and downstream pathways involving mTORC2, GLUT4 translocation, and enhanced metabolic flexibility.
“This marks a pivotal step in unlocking the full therapeutic potential of muscle-targeted β2-agonists,” said Bengtsson. “Our research elucidates a novel signaling pathway that avoids the cardiac side effects of β2-agonists and provides compelling proof that ATR-258 can actively reshape body composition – reducing fat while preserving muscle mass – all without requiring dietary restriction. That’s an unprecedented therapeutic profile.”
Combination potential and phase 2 readiness
Data from long-term animal studies revealed that ATR-258 not only improved metabolic parameters in diabetic and obese models but also protected against the muscle-wasting effects observed with GLP-1 monotherapy. The safety profile appears favorable, with no significant cardiac effects noted across extended preclinical studies in rodents and dogs, nor in the first-in-human trial involving both healthy volunteers and type 2 diabetes patients.
Bengtsson describes ATR-258 as a “dual-purpose therapy,” suited both for standalone use and in combination. “It can stand alone as a potential preventive or disease-modifying treatment for age-related sarcopenia and frailty, particularly in populations who are unable to exercise,” he explains. “At the same time, it complements GLP-1 based therapies by mitigating their well-documented drawback: loss of muscle mass.”
Associate Professor Morten Hostrup of the University of Copenhagen, a co-author on the Cell paper, commented: “This development offers patients a unique treatment option that does not require compromising muscle in the pursuit of weight loss. The potential applications of ATR-258 extend well beyond obesity and diabetes, encompassing a range of muscle-wasting conditions. By preserving muscle mass while supporting improved glucose regulation, ATR-258 may represent a significant advancement in therapeutic approaches across multiple clinical areas.”
The compound is now preparing to enter Phase 2 clinical trials, where its ability to deliver “exercise-like” benefits – namely fat reduction, muscle strengthening, and improved glycemic control – will be tested in both monotherapy and combination regimens with GLP-1 receptor agonists.
Sarcopenia, GLP-1s and the aging economy
Bengtsson emphasized the broader physiological relevance of skeletal muscle: “Muscle is one of the most important yet underappreciated organs in aging biology,” he told us, highlighting that beyond mobility, muscle contributes to glucose regulation, immune function, and overall systemic resilience. “Low muscle mass and strength are strong predictors of mortality. Loss of muscle quality contributes directly to frailty, falls, poor metabolic control, and longer recovery after illness or surgery.”
The implications extend well beyond diabetes. As societies age and the burden of sarcopenia rises, preserving muscle mass becomes not merely a health goal but an economic and social imperative. A therapy that can improve metabolic outcomes without depleting muscle may serve not just the overweight middle-aged, but also older adults struggling with frailty and declining function.
For longevity biotech, this convergence of metabolic and muscular health is likely to become a defining feature of next-generation therapeutic design – one where the ability to walk unaided may matter as much as a lowered A1C.
From numbers to function
If the next chapter in metabolic medicine lies not just in reducing excess but in restoring balance, then targeting the muscle – thoughtfully and precisely – may be one of the most intelligent strategies yet.
“Ultimately, the goal is not just to improve numbers on a chart,” Bengtsson said, “but to demonstrate enhanced resilience, mobility, and quality of life – core hallmarks of increased healthspan.” As the company advances to Phase 2, Atrogi is prioritizing muscle-centric endpoints, including DXA and MRI imaging, functional assessments and molecular biomarkers of mitochondrial activity, protein synthesis and inflammation.
“If GLP-1s were Act I,” he reflected, “ATR-258 may be Act II – preserving muscle, preventing frailty, and enabling a more robust, active later life.”
[1] https://www.cell.com/cell/fulltext/S0092-8674(25)00630-0
